NRI from all over the world (excluding U.S.A. & Canada) can invest in this fund
SBNRI is a certified Mutual Fund distributor registered with Association of Mutual Funds in India (AMFI) with Reg. No. 246671
₹130.06
0.25%
NAV as on 16 Nov 24, 12:00 AM
very high risk
contra
equity
NAV as on 16 Nov 24, 12:00 AM
very high risk
contra
equity
41.12%p.a.
Last 1Y
17.29%p.a.
Last 3Y
22.05%p.a.
Last 5Y
15.91%p.a.
Since Inception
NRIs can achieve long-term capital appreciation by investing in the Invesco India Contra Fund Growth scheme from Invesco Asset Management (India) Private Ltd. It is a Contra mutual fund scheme that predominantly invests in Contra stocks of companies. Launched on Apr 2007, Invesco India Contra Fund Growth is Contra fund of its category with 17,717.85 Cr fund under management as on Nov 2024. The expense ratio of this fund is less than that of most other Fund category Contra funds.
To generate capital appreciation by investing predominantly in Equity and Equity Related Instruments through contrarian investing.
ICICI Bank Ltd
7.23%
HDFC Bank Ltd
7.22%
Infosys Ltd
6.09%
Axis Bank Ltd
3.62%
NTPC Ltd
3.58%
REC Ltd
2.57%
Mahindra & Mahindra Ltd
2.43%
Larsen & Toubro Ltd
2.41%
Coforge Ltd
2.32%
Bharat Electronics Ltd
2.21%
View Scheme Document
If invested
per month
For a period of
Investment of ₹0 could have been
₹0(+0.0%)
₹0 (+0.0%)
This Fund
₹0 (+0.0%)
Fixed Deposit
Just like for resident investors, capital gains from mutual fund investments are subject to income tax for NRI investors.
Fund Type | Short-term Capital Gains (STCG) Tax | Long-term Capital Gains (LTCG) Tax |
---|---|---|
Equity mutual funds | 15% | 10% (above Rs. 1 lakh LTCG) without indexation* |
Debt & other types of funds | At tax slab rate | 20% with indexation benefits |
NRIs and OCIs can download the SBNRI app to invest in mutual funds from the country of their residence. Here are a few simple steps you need to take:
If all details are correct, your KYC will be approved within 7 to 8 business days.
Funds
3Y Return
very high risk | equity
21.4%
very high risk | equity
18.7%